Clinical Trial Update: Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) [Phase 2]

View source ↗

Summary

Phase II trial investigating sequential single-agent nivolumab followed by combination ipilimumab plus nivolumab in metastatic or unresectable non-clear cell re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chromophobe Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma Type
• Papillary Renal Cell Carcinoma Type 2
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma
• Xp11 Translocation Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Conditions: Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1 | Phase 2 | Status: UNKNOWN